Fragile X Treatment Pipeline: Current and Emerging Clinical Trials

Watch FRAXA’s Fragile X clinical trials webinar featuring leading researchers discussing current studies, emerging treatments, trial eligibility, and the future of the Fragile X treatment pipeline.

Read More »
Close-up illustration of a neuron and synapses symbolizing brain signaling and BK channel activity in Fragile X syndrome

Opening the Gate: BK Channel Modulation as a Promising Treatment Strategy for Fragile X Syndrome

Fragile X syndrome research is opening the door to BK channel therapies that may calm hyperexcitable brain circuits and improve key symptoms.

Read More »
Illustration of researchers presenting funding support for SPG601 fragile X syndrome clinical trial backed by FRAXA

FRAXA Backs Upcoming Phase 2B Trial of SPG601 for Fragile X Syndrome

FRAXA Research Foundation is supporting a Phase 2b clinical trial of SPG601, an experimental therapy targeting BK channels in fragile X syndrome, following promising early results.

Read More »
Craig Erickson, MD (left) and Stella Sarraf, PhD (right) on a video call for the Spinogenix SPG601 Fragile X clinical trial.

Spinogenix and FRAXA Advance SPG601 Into Phase 2b Trial for Fragile X Syndrome

Spinogenix and FRAXA are supporting a Phase 2b clinical trial of SPG601 in Fragile X syndrome, building on Phase 2 signals and FDA designations.

Read More »

SPG601 Calms Brain Activity in Men with Fragile X, Helping Them to Focus

Treatment with Spinogenix’s SPG601 showed promising results for men with Fragile X syndrome (FXS) in a Phase 2a clinical trial.

Read More »
Neuronal synapse illustration showing neurotransmitter release, symbolizing how BK channel openers restore balance in Fragile X syndrome.

BK Channel Openers: From FRAXA Seed Funding to Big Pharma Investment and Trials

See how FRAXA’s early grants propelled Fragile X research from lab discoveries to industry momentum, with partners advancing therapies into trials.

Read More »

BK Channel Openers: A New Drug for Fragile X Is Ready for Clinical Trials

A promising new BK channel opener, SPG601 from Spinogenix, is entering clinical trials for Fragile X syndrome. Learn about its potential to restore synaptic function and address core symptoms.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (40)